Boryung보령

Boryung's trailing profits have improved on higher sales, but its shares sit near the low end of their 52-week range and the company is in the middle of a company split.

Boryung is a Korean pharma company selling chronic-disease prescription drugs and OTC brands, with trailing twelve-month revenue of ₩1.06T and net income of ₩121B to H1 2026. Shares closed at ₩8,300 on 2026-10-26, about 23% below the 52-week high of ₩10,800 and near the low of ₩7,410. Filings show a pending company split and treasury share sale, and the company has released preliminary consolidated earnings.

What stands out

• Trailing operating margin is 6.9% and net margin is 11.4%, but net income is well above operating income, which the data does not explain.
• Full-year 2025 revenue was flat at ₩1.02T and operating income fell to ₩65B from ₩70B in 2024.
• Valuation metrics are low: P/E of 5.9, P/B of 0.8, and a 1.9% dividend yield, compared with peers such as Yuhan (P/E 25.4) and Celltrion (P/E 28).
• Foreign ownership fell from 6% to 4.9% over about 60 days, while retail investors were net sellers over the last 20 days.
• Recent headlines cover a Phase 2 registration for Bosmorcibu with approval filing targeted for 2028, and space life sciences partnerships.

What to watch

• Details of the company split and the treasury share sale, which were filed in September 2026 and amended later.
• Full H1 2026 results and the detail behind the preliminary consolidated earnings released on 2026-10-22.
• Borrowings of ₩236B against ₩50B of cash, and the discounted cash flow model's wide range from ₩7,918 (bear) to ₩28,891 (bull).